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Cystic ﬁbrosis (CF) is one of the most common indications for preimplantation genetic diagnosis (PGD) for single gene disorders,
giving couples the opportunity to conceive unaffected children without having to consider termination of pregnancy. However,
there are no available standardized protocols, so that each center has to develop its own diagnostic strategies and procedures.
Furthermore, reproductive decisions are complicated by the diversity of disease-causing variants in the CFTR (cystic ﬁbrosis
transmembrane conductance regulator) gene and the complexity of correlations between genotypes and associated phenotypes,
so that attitudes and practices toward the risks for future offspring can vary greatly between countries. On behalf of the
EuroGentest Network, eighteen experts in PGD and/or molecular diagnosis of CF from seven countries attended a workshop held
in Montpellier, France, on 14 December 2011. Building on the best practice guidelines for ampliﬁcation-based PGD established
by ESHRE (European Society of Human Reproduction and Embryology), the goal of this meeting was to formulate speciﬁc
guidelines for CF-PGD in order to contribute to a better harmonization of practices across Europe. Different topics were covered
including variant nomenclature, inclusion criteria, genetic counseling, PGD strategy and reporting of results. The
recommendations are summarized here, and updated information on the clinical signiﬁcance of CFTR variants and associated
phenotypes is presented.
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INTRODUCTION
Cystic ﬁbrosis (CF, OMIM #219700) is one of the most common
life-shortening autosomal recessive disorders in populations of
European descent, affecting about 1 in 4000 individuals.1 It is also
present in most other ethnicities, but the disease frequency varies
greatly. CF is caused by sequence variations in the Cystic ﬁbrosis
transmembrane conductance regulator (CFTR, OMIM #602421) gene
on 7q31.2, which lead to absent or decreased chloride and bicarbonate
transports across the apical membranes of secretory epithelial cells,
elevated intracellular sodium and decreased extracellular water.
This results in thickened secretions in affected structures (airways,
pancreatic and biliary ducts, intestines and vas deferens). Although the
severity of symptoms is variable, most patients with CF typically
present progressive obstructive lung disease with persistent airway
colonization and bronchiectasis, pancreatic insufﬁciency, gastro-
intestinal and nutritional anomalies, abnormally high sweat chloride
levels and male infertility due to absent or occluded vasa deferentia.
Early detection of CF through newborn screening programs is of
major importance for the improvement of both survival and quality of
life of patients.2–4
Close to 2000 unique variations have been identiﬁed so far in the
CFTR gene (http://www.genet.sickkids.on.ca), either in CF, in CFTR-
related disorders (CFTR-RD), or in asymptomatic individuals. The
term CFTR-RD refers to a distinct spectrum of nonlethal diseases that
do not fulﬁll diagnostic criteria for CF but show evidence
of CFTR dysfunction,5 including congenital bilateral absence of
vas deferens (CBAVD),6–12 recurrent pancreatitis,13,14 disseminated
bronchiectasis,15 or CFTR-related metabolic syndrome16 (Box 1,
Table 1). Besides the most common CF disease-causing variant,
a 3-bp deletion c.1521_1523delCTT known as p.Phe508del, that
accounts for approximately 67% of CFTR mutant alleles in Europe,
another 130 variants have been clinically, genetically and experimen-
tally classiﬁed as CF-causing.17 The clinical consequences of many
other variants, particularly those that change an amino acid in the
protein (missense variants) are largely uncharacterized. In addition,
some pathogenic variants are not necessarily fully penetrant18 (eg their
deleterious effect depends on other factors). The number of variants of
unknown (clinical) signiﬁcance (VUCS or VUS) is predicted to
increase with the expansion of next generation sequencing methods
for CF carrier screening, which is among the ﬁrst general population
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genetic screening tests, with worldwide probably more than 10
millions tests each year. Assessing disease causality for CFTR variants
is extremely challenging18–20 owing to their number and variety21 and
the complexity of genotype-phenotype relationship in CF or CFTR-
RDs (some identical genotypes may be associated with different
phenotypes). Interpreting CFTR variations as ‘pathogenic’ or ‘neutral’
and, beyond, as ‘CF-causing’ or ‘non CF-causing’, has evident impact
on diagnosis, genetic counseling and reproductive choices of patients
and families.
Evidence from practice indicates that whilst natural conception
followed by prenatal diagnostic (PND) was in the past the most
common reproductive choice for many couples at risk of passing on
CF, preimplantation genetic diagnosis (PGD) is increasingly being
seen as a preferred choice. So far, the most used approach for PGD for
CF involves the biopsy of one blastomere from 3 days-old embryos
following ICSI (intracytoplasmic sperm injection) at the 6–10 cell
stage.22 Blastomeres are then analyzed and embryos shown to be free
of the disease are transferred to the maternal uterus. This procedure
Box 1 The spectrum of CFTR-associated diseases
✓ Classical or typical cystic ﬁbrosis (CF) includes the following features:
 Chronic sinopulmonary disease with persistent colonization with typical CF pathogens,
 Speciﬁc gastrointestinal or nutritional abnormalities,
 Salt-loss syndromes,
 Obstructive azoospermia,
 Abnormal sweat test (chloride concentration ≥60mmol/l),
 Two CF-causing variants in trans.
Over 85% of these patients have two severe CF-causing variants and are pancreatic insufﬁcient (CF-PI). A minority of CF patients carry at least one ‘moderate’ variant,
which confers some residual CFTR channel function maintaining sufﬁcient exocrine pancreatic function to allow normal digestion of nutrients (pancreatic sufﬁciency, CF-
PS).
In many countries, CF is now diagnosed through newborn screening detecting abnormal values of immunoreactive trypsinogen in the blood, on the basis of abnormal
sweat test and two CF-causing variants.
✓ Nonclassical or atypical CF
A small proportion of patients have symptoms characteristic of CF in at least one organ but a negative (o30mmol/l) or borderline (30–60mmol/l) sweat test. They are
CF-PS and exhibit a milder and late lung disease. The diagnosis is conﬁrmed by the identiﬁcation of variants (either one mild in trans with a severe one, or two mild
variants), and by abnormal nasal potential difference measurement or intestinal current measurement using rectal biopsy. Individuals in this group have an increased risk
of pancreatitis.
✓ CFTR-related disorders (CFTR-RD)5
A CFTR-RD is deﬁned as a clinical entity with evident CFTR dysfunction that does not fulﬁll the CF diagnostic criteria. Three distinct subgroups must be distinguished:
congenital bilateral absence of the vas deferens, acute recurrent or chronic pancreatitis, and disseminated bronchiectasis.
Congenital bilateral absence of the vas deferens (CBAVD)6–12
CBAVD is the most common cause of infertility in otherwise healthy males, with an incidence of 1:1000 men, and is present in all ethnicities. The male reproductive
tract is the most sensitive tissue to CFTR dysfunction, so that CFTR variations not severe enough to cause CF can be responsible for vas deferens aplasia. Up to 80% of
CBAVD men have two CFTR variants in compound heterozygosity, whereas 20% have either only one or no variant. None of CBAVD men carry two severe CFTR variants:
the vast majority carry a mild in trans with a severe variant, and a minor proportion has two mild variants. In CBAVD men from European descent, the two most common
genotypes are p.Phe508del in trans either with the ‘5T allele’ in intron 8 (now designated as c.1210-12T[5] in intron 9) (30%) or with the variants R117H-7T (p.
Arg117His associated with a 7T allele (c.1210-12T[7]) (6%). In humans, the variant 5T, also present in the general population at a frequency of 0.05, alters the splicing
signals and leads to the skipping of exon 9 (10 in the HGVS nomenclature) in a proportion of transcripts. The skipping varies among tissues and individuals, which
generates a proportion of incomplete and nonfunctional CFTR proteins; the result is a reduced quantity of normal CFTR protein. The disease penetrance of 5T is
incomplete (some men carrying a 5T in trans with a severe variant are fertile), and is inﬂuenced by another polymorphic sequence immediately upstream, the ‘TG tract’:
the longer the TGn and the shorter the Tn repeats are, the greater is the reduction in full-length CFTR transcripts. CBAVD is more likely to occur in males carrying a 5T
associated in cis with 12TG (c.[1210-34TG[12];1210-12T[5]] or 13TG (c.[1210-34TG[13];1210-12T[5]] than 11TG (c.[1210-34TG[11];1210-12T[5]] repeats. Thus
the determination of TG repeat number is predictive of the pathogenicity of the 5T alleles.
Spermatogenesis in CBAVD males is normal, thus patients can be treated by sperm extraction followed by ICSI. If the female partner also carries a CF-causing variant,
the offspring has an increased risk (25%) of CF (the CF variants of both partners), and male offspring have, depending on the penetrance of mild variants, up to 25%
additional chance of having CBAVD (the mild variant of the father and the CF variant of the mother). Genetic counselling may be particularly difﬁcult in couples with a
CBAVD partner as they often carry variants with a wide range of effects from normal to CFTR-RD.11,12
Idiopathic chronic pancreatitis and recurrent acute pancreatitis: approximately 30% of individuals in this group who do not fulﬁll the diagnostic criteria for CF are found
with at least one CFTR variant and sweat chloride values in the intermediate range.13 They include a small proportion with compound heterozygosity for a CF-causing and
a mild CFTR variant (including the 5T allele) and a majority of carriers of a single CF or CFTR-RD variant with increased susceptibility to pancreas dysfunction. Recent
studies suggest that certain missense variants could selectively alter the bicarbonate transport while chloride function is preserved, thus affecting only tissues that
necessitate CFTR for bicarbonate secretion such as pancreas.14
Disseminated bronchiectasis: 15–25% of individuals with abnormal and irreversible dilatation of thick-walled bronchi are found to carry CFTR variants, mostly with
residual CFTR function (including a high proportion of allele 5T) and mostly in the heterozygous state. CFTR variants may act as risk alleles for multigenic disorders in the
general population.15
CFTR-related metabolic syndrome (CRMS): Asymptomatic newborns with an inconclusive diagnosis following a positive NBS test (abnormal immunoreactive
trypsinogen levels but nondiagnostic sweat chloride or genetic analysis). They may either remain symptom free or develop mild CF or CFTR-RD later in life, and therefore
need regular follow-up.16
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avoids the dilemma of therapeutic abortion following PND by
chorionic villus sampling or amniocentesis in the ﬁrst or second
trimester of pregnancy. As the blastomere biopsy procedure on day 3
can be traumatic to the embryo, reducing its developmental potential,
there is an increasing tendency to move to the day 5 or 6
trophectoderm biopsy at the blastocyst stage.23 However, blastocyst
biopsy is more challenging than blastomere biopsy, and only some
centers (especially those that test PGD embryos for aneuploidy24) have
changed their protocols so far. CF is one of the most common
indications of PGD worldwide, accounting for almost 10% of all
indications for monogenic disorders, as recorded in the European
Society of Human Reproduction and Embryology (ESHRE) PGD
consortium data collection XII.25
Best practice guidelines for ampliﬁcation-based PGD dealing
with infrastructures, equipment and materials as well as molecular
procedures (pre-examination, examination and post-examinations
processes) have been established and updated by the ESHRE
consortium.26,27 These guidelines describe general recommendations
on genetic practices for PGD programs, in order to build a consensus
opinion on best practices within the PGD community and to achieve a
minimum standard across all centers. However, due to the absence of
a universal, standardized PGD assay, each center develops its own in-
house methods. Such methods are based on direct screening of speciﬁc
variants,28,29 linkage analysis using informative microsatellites,30,31 or a
combination of direct and indirect testing.32,33 Some centers use
ﬂuorescent multiplex PCR protocols, others perform nested PCRs, and
a few centers use Whole Genome Ampliﬁcation techniques (mainly
Multiple Displacement Ampliﬁcation, MDA) to generate larger
quantities of DNA template, followed by haplotyping of several
polymorphic markers.34,35
Many health practitioners, even among highly trained specialists in
academic medical institutions and including those in reproductive
medicine, wish more information about genetic testing and
counseling.36 The guidelines presented here are the result of a meeting
held in December 2011 with the partnership of EuroGentest (www.
eurogentest.org). The main purpose of the meeting was to formulate
more speciﬁc PGD guidelines for CF-PGD, in line with the general
guidelines for ampliﬁcation-based PGD,27 for organization of a PGD
center for PGD/PGS37 and for polar body and embryo biopsy38
previously published by ESHRE. The speciﬁc guidelines are based
on experience with CFTR genetic testing, and will contribute to the
harmonization and quality of procedures, methods and protocols
and to the standardization of reporting results for cystic ﬁbrosis.
We also present updated information on CFTR variation including
nomenclature, classiﬁcation of variants, and genotype-phenotype
correlations.
MATERIALS AND METHODS
In order to discuss relevant technical and genetic issues in PGD for cystic
ﬁbrosis, a ‘Best practice guidelines for CF-PGD meeting’ was held in
Montpellier, France, on 14 December 2011. The meeting brought together
eighteen experts in the ﬁelds of PGD and molecular diagnosis of CF and CFTR-
RDs from seven countries (Spain, Belgium, Italy, USA, UK, Greece and France).
Presentations and subsequent discussions formed the basis for establishing
speciﬁc guidelines.
NOMENCLATURE
Since the discovery of the CFTR gene in 1989, the CF scientiﬁc
community developed its own nomenclature system (Cystic Fibrosis
Mutation Database, (http://www.genet.sickkids.on.ca/)). Despite the
introduction of a worldwide standardized Human Genome Variation
Society (HGVS) nomenclature,39,40 the original (‘legacy’) names are
still commonly used for CFTR variants and polymorphisms in clinical
services, whereas diagnostic laboratories use both nomenclatures
simultaneously to ensure compatibility with previous clinical reports
and understanding by clinicians and couples. The HGVS DNA variant
numbering system is based on cDNA, deﬁning position ‘+1’ as the A
of the ATG translation initiation codon in the CFTR reference
sequence (NM_000492.3), with initiation codon as codon 1 and
exons numbered 1–27. In contrast, in the legacy (traditional)
annotation, ‘+1’ was the ﬁrst base of the mRNA major transcript,
and the A of the ATG was consequently nucleotide 133. These two
different nomenclatures can lead to confusion and serious erroneous
interpretation and reporting of the location of variants. For example,
the well-known 1717-1G4A and 3120+1G4A variants (legacy
names) are designated as c.1585-1G4A and c.2988+1G4A, respec-
tively, according to the HGVS nomenclature. Not being aware of
nomenclature changes and testing a variant at a wrong position in the
gene will ultimately lead to erroneous PND or PGD. Variants
nomenclature is a complex and evolving process, therefore constant
vigilance is needed for accurate reporting.41
It is strongly recommended to obtain the original molecular genetic
reports including the description of identiﬁed variants in both the
HGVS and legacy nomenclatures. Then, it is recommended to verify
the reported variants on new DNA samples from the couples, using
standard molecular techniques (Box 2).
Traditional and HGVS nomenclatures for the most common
CF-causing, non CF-causing and variants with varying clinical
consequences, and examples of common CFTR genotypes nomencla-
tures, are presented in Tables 1 and 2, respectively. Useful Internet
resources are compiled in Box 3.
INCLUSION CRITERIA
Multiple occasions arise to detect individuals carrying CFTR variants
(Table 3), who may become future candidates for PGD. Some variants
are not causing CF but have been included in commercially available
population-based carrier screening panels. These kits may be used by
accredited and non-accredited laboratories, thus accreditation does
not guarantee the non-detection of clinically non-signiﬁcant variants.
Couples may not have been correctly counseled about the risks.42,43
Before enrolling a couple for a PGD procedure for CF, it is
recommended to evaluate within a multidisciplinary team whether
the variants identiﬁed in both partners should be considered for PND
or PGD. Variants may be grouped in four categories: (i) loss-of-
Box 2 Importance of verifying the presence of variants initially
reported in each member of the couple requesting a CF-PGD
Analysing the DNA of each member of the couple will conﬁrm the initial result
and will conﬁrm that both parents carry at least one CF-causing variant.
For example, inability to conﬁrm the variants in both parents may be found in
cases with apparent homozygosity for a common or a rare variant:
 Nonpaternity
 Presence on the opposite allele of a large deletion, nonrevealed by routine
tests
 Presence of a rare SNP in primer-binding sites or a rare DNA variant that
causes failure of ampliﬁcation and/or hybridization of a probe: for example,
false homozygosity for p.Phe508del due to the presence of the variant F508C
(c.1523T4G); false homozygosity for p.Ile507del due to the presence of
p.Ile507Val (I597V) (c.1519A4G).
 Uniparental disomy of chromosome 7, more rarely.
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Table 1 Examples of common CF-causing, indetermined, and non
CF-causing variants (modiﬁed from5,8,17)
HGVS nomenclature
Legacy name cDNA nucleotide name Protein name
CF-causing variantsa
F508del c.1521_1523delCTT p.Phe508del
G542X c.1624G4T p.Gly542*
G551D c.1652G4A p.Gly551Asp
N1303K c.3909C4G p.Asn1303Lys
W1282X c.3846G4A p.Trp1282*
621+1G4T c.489+1G4T
CFTRdele2,3 c.54-5940_273
+10250del21080
p.Ser18Argfs*16
E60X c.178G4T p.Glu60*
G85E c.254G4A p.Gly85Glu
394delTT c.262_263delTT p.Leu88Ilefs*22
711+1G4T c.579+1G4T
R347P c.1040G4C p.Arg347Pro
A455E c.1364C4A p.Ala455Glu
Q493X c.1477C4T p.Gln493*
I507del c.1519_1521delATC p.Ile507del
R553X c.1657C4T p.Arg553*
R560T c.1679G4C p.Arg560Thr
1898+1G4A c.1766+1G4A
2183AA4G c.2051_2052delAAinsG p.Lys684Serfs*38
2789+5G4A c.2657+5G4A
3120+1G4A c.2988+1G4A
M1101K c.3302 T4A p.Met1101Lys
R1162X c.3484C4T p.Arg1162*
3659delC c.3528delC p.Lys1177Serfs*15
M1V c.1 A4G p.? (unknown)
Q39X c.115C4T p.Gln39*
P67L c.200C4T p.Pro67Leu
R75X c.223C4T p.Arg75*
405+1G4A c.273+1G4A
406-1G4A c.274-1G4A
E92X c.274G4T p.Glu92*
E92K c.274G4A p.Glu92Lys
Q98X c.292C4T p.Gln98*
457TAT4G c.325_327delTATinsG p.Tyr109Glyfs*4
D110H c.328G4C p.Asp110His
R117C c.349C4T p.Arg117Cys
Y122X c.366 T4A p.Tyr122*
574delA c.442delA p.Ile148Leufs*5
444delA c.313delA p.Ile105Serfs*2
663delT c.531delT p.Ile177Metfs*12
G178R c.532G4A p.Gly178Arg
711+3A4G c.579+3A4G
711+5G4A c.579+5G4A
712-1G4T c.580-1G4T
H199Y c.595C4T p.His199Tyr
P205S c.613C4T p.Pro205Ser
L206W c.617 T4G p.Leu206Trp
Q220X c.658C4T p.Gln220*
852del22 c.720_741delAGGGAGAAT
GATGATGAAGTAC
p.Gly241Glufs*13
1078delT c.948delT p.Phe316Leufs*12
G330X c.988G4T p.Gly330*
Table 1 (Continued )
HGVS nomenclature
Legacy name cDNA nucleotide name Protein name
R334W c.1000C4T p.Arg334Trp
I336K c.1007 T4A p.Ile336Lys
T338I c.1013C4T p.Thr338Ile
1154insTC c.1021_1022dupTC p.Phe342Hisfs*28
S341P c.1021 T4C p.Ser341Pro
R347H c.1040G4A p.Arg347His
1213delT c.1081delT p.Trp361Glyfs*8
1248+1G4A c.1116+1G4A
1259insA c.1130dupA p.Gln378Alafs*4
W401X(TAG) c.1202G4A p.Trp401*
W401X(TGA) c.1203G4A p.Trp401*
1341+1G4A c.1209+1G4A
1461ins4 c.1329_1330insAGAT p.Ile444Argfs*3
1525-1G4A c.1393-1G4A
S466X c.1397C4A or c.1397C4G p.Ser466*
L467P c.1400 T4C p.Leu467Pro
S489X c.1466C4A p.Ser489*
S492F c.1475C4T p.Ser492Phe
1677delTA c.1545_1546delTA p.Tyr515*
V520F c.1558G4T p.Val520Phe
1717-1G4A c.1585-1G4A
1717-8G4A c.1585-8G4A
S549R c.1645 A4C p.Ser549Arg
S549N c.1646G4A p.Ser549Asn
S549R c.1647 T4G p.Ser549Arg
Q552X c.1654C4T p.Gln552*
A559T c.1675G4A p.Ala559Thr
1811+1.6kbA4G c.1680-886A4G
1812-1G4A c.1680-1G4A
R560K c.1679G4A p.Arg560Lys
E585X c.1753G4T p.Glu585*
1898+3 A4G c.1766+3A4G
2143delT c.2012delT p.Leu671*
2184insA c.2052_2053insA p.Gln685Thrfs*4
2184delA c.2052delA p.Lys684Asnfs*38
R709X c.2125C4T p.Arg709*
K710X c.2128 A4T p.Lys710*
2307insA c.2175dupA p.Glu726Argfs*4
L732X c.2195 T4G p.Leu732*
2347delG c.2215delG p.Val739Tyrfs*16
R764X c.2290C4T p.Arg764*
2585delT c.2453delT p.Leu818Trpfs*3
E822X c.2464G4T p.Glu822*
2622+1G4A c.2490+1G4A
E831X c.2491G4T p.Glu831*
W846X c.2537G4A p.Trp846*
W846X
(2670TGG4TGA)
c.2538G4A p.Trp846*
R851X c.2551C4T p.Arg851*
2711delT c.2583delT p.Phe861Leufs*3
S945L c.2834C4T p.Ser945Leu
2789+2insA c.2657+2_2657+3insA
Q890X c.2668C4T p.Gln890*
L927P c.2780 T4C p.Leu927Pro
3007delG c.2875delG p.Ala959Hisfs*9
G970R c.2908G4C p.Gly970Arg
3120G4A c.2988G4A
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function variants that cause CF disease when paired together;
(ii) variants that retain residual CFTR function and are compatible
with milder phenotypes such as CFTR-RD; (iii) variants with no
clinical consequences; and (iv) variants of unproven or uncertain
clinical relevance. A recent survey of genotype and phenotype data
from almost 40 000 individuals recorded as ‘affected with CF’ in the
clinical registries in Europe and North America, in conjunction with
functional assessment, allowed to redeﬁne the disease liability of
159 common variants in the CFTR gene.17 However, the disease
penetrance of the vast majority of hundreds of rare missense variants
identiﬁed so far remains unknown. It is therefore recommended to
work in close collaboration with specialized clinical geneticists and
reference laboratories that have gained considerable knowledge in the
interpretation of CFTR variants.
Otherwise, with respect to variations in local or national regulations
and speciﬁc laboratory practices, the Montpellier meeting revealed
some discrepancies in the way that couples are included or not in
CF-PGD programs (Table 4). In several countries, when at least one
Table 1 (Continued )
HGVS nomenclature
Legacy name cDNA nucleotide name Protein name
3121-1G4A c.2989-1G4A
3199del6 (3195del6) c.3067_3072delATAGTG p.Ile1023_Val1024del
3272-26 A4G c.3140-26 A4G
L1065P c.3194 T4C p.Leu1065Pro
R1066C c.3196C4T p.Arg1066Cys
R1066H c.3197G4A p.Arg1066His
L1077P c.3230 T4C p.Leu1077Pro
W1089X c.3266G4A p.Trp1089*
Y1092X c.3276C4A p.Tyr1092*
E1104X c.3310G4T p.Glu1104*
R1158X c.3472C4T p.Arg1158*
S1196X c.3587C4G p.Ser1196*
W1204X(3743G4A) c.3611G4A p.Trp1204*
W1204X(3744G4A) c.3612G4A p.Trp1204*
3791delC c.3659delC p.Thr1220Lysfs*8
3849+10kbC4T c.3718-2477C4T p.(?)
G1244E c.3731G4A p.Gly1244Glu
3876delA c.3744delA p.Lys1250Argfs*9
S1251N c.3752G4A p.Ser1251Asn
3905insT c.3773dupT p.Leu1258Phefs*7
4005+1G4A c.3873+1G4A
4016insT c.3889dupT p.Ser1297Phefs*5
Q1313X c.3937C4T p.Gln1313*
CFTRdele22,23 c.3964-78_4242+577del p.(Gly1323_Val1415del)
4209TGTT4AA c.4077_4080delTGTTinsAA
4382delA c.4251delA p.Glu1418Argfs*14
Examples of common variants with varying or indetermined clinical consequencesb
R117H c.350G4A p.Arg117His
L227R c.680 T4G p.Leu227Arg
Q359K/T360K c.[1075C4A;1079C4A] p.[Gln359Lys;
Thr360Lys]
L558S c.1673 T4C p.Leu558Ser
Y569D c.1705 T4G p.Tyr569Asp
D579G c.1736 A4G p.Asp579Gly
D614G c.1841 A4G p.Asp614Gly
S977F c.2930C4T p.Ser977Phe
F1052V c.3154 T4G p.Phe1052Val
G1069R c.3205G4A p.Gly1069Arg
R1070Q c.3209G4A p.Arg1070Gln
D1152H c.3454G4C p.Asp1152His
I1234V c.3700 A4G p.Ile1234Val
5T c.1210−12[5]
Examples of common not CF-causing variantsc
R31C c.91C4T p.Arg31Cys
R74W c.220C4T p.Arg74Trp
R75Q c.224G4A p.Arg75Gln
I148T c.443 T4C p.Ile148Thr
M470V c.1408 A4G p.Met470Val
G576A c.1727G4C p.Gly576Ala
R668C c.2002C4T p.Arg668Cys
V754M c.2260G4A p.Val754Met
L997F c.2991G4C p.Leu997Phe
I1027T c.3080 T4C p.Ile1027Thr
R1070W c.3208C4T p.Arg1070Trp
R1162L c.3485G4T p.Arg1162Leu
Table 1 (Continued )
HGVS nomenclature
Legacy name cDNA nucleotide name Protein name
S1235R c.3705 T4G p.Ser1235Arg
D1270N c.3808G4A p.Asp1270Asn
7T c.1210-12[7]
Abbreviation: HGVS, Human Genome Variation Society.
aCF-causing variants: when paired together in trans, they cause cystic ﬁbrosis in most patients*.
The six most frequent non-p.Phe508del variants are listed ﬁrst followed by 18 other common
variants, then 110 other variants are listed by cDNA nucleotide numbering (middle column).
CF-causing variants include: (i) variants that are predicted to introduce a premature termination
codon (PTC) into CFTR mRNA and therefore result in absence of protein such as nonsense
variants (sequence changes that introduce a stop codon), variants that affect canonical
nucleotides of the donor or acceptor splice sites (gt or ag) or insertions and deletions that cause
a frameshift of the ORF (Open Reading Frame); (ii) variants occurring within or near splice sites
that lead to severe reduction (490%) in the level of full-length CFTR mRNA and CFTR protein;
(iii) missense variants that drastically alter folding, processing, trafﬁcking and/or function of
CFTR protein. *However, several variants in the list above may retain residual function and can
be found either in CF or in CFTR-RDs. Well known examples include missense variants D110H,
R117C, L206W, R347P, R347H, R1066H, or splice variants that produce both aberrant and
full-length transcript such as 3849+10kbC4T, 2789+5G4A, 3272-26 A4G, 711+3 A4G.
bVariants with varying or indetermined clinical consequences: when paired with a severe variant
in trans, they cause either no disease phenotype, or CFTR-RD or mild CF-PS. The 5 T allele is
the most common allele associated with CFTR-RDs worldwide. The disease penetrance of some
of these variants is dependent on other factors, such as other sequence changes associated in
cis. The most studied examples are R117H and the 5 T allele. When paired in trans with a
severe CF variant, R117H is considered as causing CFTR-RD (or rarely mild CF-PS) if
associated in cis with a 5 T allele (rare occurence), whereas it is considered as a neutral or
CFTR-RD variant when associated in cis with the common 7 T allele.11 Owing to the extremely
low penetrance of R117H for CF,18 in some countries this variant has been removed from the
newborn CF screening panels, as its presence created both management and counseling
dilemmas (many healthy carriers of R117H-7 T could be wrongly considered as CF carriers and
prenatal diagnosis inappropriately proposed).
cNon CF-causing variants: when paired with a severe variant in trans, they cause usually no
disease phenotype, or a CFTR-RD in some individuals. Missense variants R74W, R1070W,
D1270N are classiﬁed as ‘indeterminate’ by Sosnay et al.,17 however, as they are frequently
found in trans with a severe CF variant in asymptomatic individuals (including fertile fathers),
they may not be sufﬁcient to cause disease.19 Moreover, they are often associated within the
same allele (eg in cis), forming various combinations (‘complex alleles’) depending on
individuals, so that their disease liability is questionable.
Examples:
[R74W;D1270N] c.[220C4T;3808G4A]
[R74W;V201M;D1270N] c.[220C4T;601G4A;3808G4A]
[R74W;R1070W;D1270N] c.[220C4T;c.3208C4T;3808G4A]
I148T is a neutral variant, but can be associated in cis with a severe CF variant
c.3067_3072del (legacy 3199del6 or 3195del6) that, in isolation causes CF, whereas I148T
in isolation does not.19,20 G576A is found in cis with R668C and R668C can be found alone or
in cis with G576A. I1027T is usually found in cis with F508del:
Notes: (i) Some missense variants classiﬁed as either indeterminate or non CF-causing (R74Q,
R75Q, R117H, R170H, L967S, L997F, D1152H, S1235R and D1270N) can selectively alter
the bicarbonate permeation of the CFTR channel (but not the chloride channel), thus affecting
primarily the organs that utilize CFTR for bicarbonate secretion (pancreas, nasal sinus, or vas
deferens) and, consequently, they could be involved in the pathogenic mechanisms of CFTR-
RDs.14 (ii) In Table 1, the traditional name of common CFTR variants is referenced alongside
the HGVS version in order to ensure compatibility with clinical reports and understanding by
clinicians and couples. In the associated text, for reasons of space, some CFTR variants may be
referred using traditional names.
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severe CF-causing or large spectrum variant is identiﬁed in one of the
members of the couple, PGD is accepted even though a mild or
benign variant is found in the other partner. This is an exclusion
criterion in France where PGD is restricted to couples ‘having a high
probability to give birth to a child affected by a particularly severe genetic
disease and recognized as being incurable at the time of diagnosis’.
Consequently, only the risk of transmitting CF (and not milder
phenotypes such as CFTR-RD) is considered for PGD. In the UK,
when one couple member is heterozygous for a variant of unproven or
uncertain clinical relevance, PGD is accepted only in the context of a
Table 2 Examples of CFTR genotypes in traditional (legacy) and HGVS nomenclatures (modiﬁed and updated from Berwouts et al., 2011)41
CFTR testing result Traditional HGVS DNA nucleotide name
No variant detected normal/normal c.[=];[=]
Heterozygote carrier F508del/normal c.[1521_1523delCTT];[=]
One variant found in a CF patient F508del/unknown c.[1521_1523delCTT];[?]
Compound heterozygote (two alleles in trans)a F508del/621+1G4T c.[1521_1523delCTT];[489+1G4T]
Two variants, phase unknown example 1b F508del and G551D c.[1521_1523delCTT(;)1652G4A]
Two variants, phase unknown example 2b 3849+10kbC4T and N1303K c.[3718-2477C4T(;)3909C4G]
Two heterozygote variants on one allele (in cis) R117H-T5/normal c.[350G4A;1210-12 T[5]];[=]
Compound heterozygote for polyT variants T5/T7 c.[1210-12 T[5]];[1210-12 T[7]]
Compound heterozygote for the 5 T allele and a CF variant T5/F508del c.[1210-12 T[5]];[1521_1523delCTT]
Compound heterozygote for polyTG-T variants and a CF variant TG12-T5/F508del c.[1210-34TG[12];1210-12 T[5]];[1521_1523delCTT]
‘c.’ indicates a coding DNA sequence. In the HGVS nomenclature, variations are described at the nucleotide level because the use of a protein-based nomenclature may be equivocal. Example:
p.Phe508del can be caused by different sequence changes at the DNA level, including c.1521_1523delCTT and c.1522_1524delTTT. See the HGVS nomenclature website (http://www.hgvs.org/
mutnomen/recs.html) for detailed descriptions of sequence variants and signiﬁcance of punctuation symbols.
aThe term ‘compound heterozygote’ means that the phase of variants has been checked by testing both parents, which conﬁrmed that each of them is a carrier of one of the two variants, which
consequently are in trans (on opposite chromosomes) in the affected individual.
bThe phase of the two variants has not been checked by parental testing: compound heterozygosity cannot be conﬁrmed.
Box 3 Internet resources
CF-Network EQA—External Quality Assessment process http://www.cfnetwork.be
United Kingdom National External Quality Assessment Service for Molecular Genetics (UKNEQAS) http://www.ukneqas-molgen.org.uk
EuroGentest http://www.eurogentest.org/web/qa/basic/xhtml
HGVS nomenclature http://www.hgvs.org/mutnomen/
European Molecular Genetics Quality Network (EMQN) http://www.emqn.org/emqn/Best+Practice
Cystic Fibrosis Mutation Database http://www.genet.sickkids.on.ca/
CFTR2 http://www.cftr2.org
Testing guidelines for molecular diagnosis of cystic ﬁbrosis (2008) www.acgs.uk.com/media/774379/cfbp26may.pdf
Orphanet www.orpha.net
OCDE guidelines for quality assurance in molecular genetic testing http://www.oecd.org/sti/biotech/38839788.pdf
University of California Santa Cruz (UCSC) genome browser http://genome.ucsc.edu
Table 3 Main indications for CFTR testing
Newborn screening for CF
Diagnostic testing
Typical CF clinical presentations (including newborns with meconium ileus)
Atypical clinical presentations and/or borderline or negative sweat test
Male infertility with CBAVD
CFTR-Related Disorder in adults
Fetuses with bowel hyperechogenicity and/or loop dilatation in the second
trimester of pregnancy (risk of CF estimated as 3%)
Carrier testing
Individuals with a family history of CF (‘cascade testing’)
Individuals without a family history (essentially for preconception carrier
screening)
Partner of a CF patient
Partner of a CBAVD patient
Infertile couples seeking for IVF (not usually recommended among European
genetic societies, as the risk of carrying a CF variant is not signiﬁcantly higher than
that of the general population).
Prenatal diagnosis, Preimplantation genetic diagnosis, offered to
Parents of a CF patient
Carrier couples identiﬁed through carrier testing
Carrier couples identiﬁed through investigations for fetal bowel anomalies
Couples with one individual affected with CF and a carrier partner
Couples with one individual affected with CBAVD and a carrier partner
Table 4 Inclusion and exclusion criteria for CF-PGD according to
countries
France Italy Spain Belgium Greece UK USA
Parents
1 affected+1 carrier S/LS A A A A A A A
1 affected+1 carrier M R A A A A A A
1 affected+1 carrier U A A A A R A★ A
2 carriers S/LS A A A A A A A
1 carrier S/LS+1 carrier M R A A A A A A
1 carrier S/LS+1 carrier U A A A A R A★ A
Abbreviations: S, severe CF-causing variant (p.Phe508del, p.Gly542★…); LS, large spectrum
variant (p.Leu206Trp, c.2657+5G4A …); M, mild variant with variable disease penetrance
(IVS8-5 T allele, p.Arg117His-7 T …); U, variants of unproven or uncertain CF clinical relevance
(p.Pro1013His, p.Arg1162Leu …); A, accepted; R, refused.
★In the context of a family history of Cystic Fibrosis (see text). Population carrier screening is
not performed in the UK.
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family history of CF. As a precaution, in all participating centres, novel
rare variants of unproven or uncertain clinical signiﬁcance may be
considered as potentially CF-causing upon advice of specialists of
CFTR alterations.
GENETIC COUNSELING AND EMBRYO TRANSFER
Similarly, discrepancies in the regulations about embryo transfer may
exist from one country to another. It is recommended that all couples
are individually counseled before the clinical cycle and the expected
embryo genotypes and corresponding phenotypes are clearly
explained.
(i) Rare variants or variants with incomplete penetrance in disease
Couples should be aware that in case of a genotype that includes
rare variants with incomplete penetrance, individual outcomes cannot
be reliably predicted. For instance, an embryo with p.Phe508del
in trans with the 5T allele (genotype c.[1210-12 T[5]];
[1521_1523delCTT]) may be considered as suitable for transfer in
some countries, while in others the parents’ wish to preferentially
transfer carrier embryos without the IVS8-5 T allele is taken into
account. In countries in which embryos compound heterozygous for a
severe and a mild/benign variant may be transferred, couples should
be informed of possible risks for their children, ranging from no
clinical signs to moderate and/or late-onset phenotypes. Some
common or rare CFTR variants are associated with a wide phenotypic
spectrum and updated information should be provided in light of
current knowledge (Table 1).
(ii) Selection of embryos for transfer
Couples should be informed that following the identiﬁcation of
genetically transferable embryos a subsequent selection is made based
upon the morphology of the embryo and its potential to implant.
Thus morphology rather than distinction between carrier embryos and
embryos free of both parental germ-line variants, forms the basis of
the ﬁnal selection of the embryo for transfer. Some centres may also
include aneuploidy screening in the PGD protocol in order to achieve
higher implantation and live birth rates. In these cases, couples need to
be appropriately counseled as the identiﬁcation of aneuploidy may
exclude embryos that had been considered transferable on the basis of
CFTR analysis alone. Couples should also be made aware that
diagnosis may not be achieved for some embryos for various reasons
including a failure of ampliﬁcation or due to cumulus cell
contamination. It is useful for the IVF unit to know the live birth
rate per cycle started for CF-PGD at their center as well as the
outcome following transfer after cryopreservation of surplus transfer-
able embryos. Multiplex PCR protocols have proven to be robust,
sensitive and highly accurate,12,31 however it is recommended in most
countries that the results should be conﬁrmed with a prenatal
diagnostic test.
PGD STRATEGY
Recommended strategies and decision procedures for PGD are
presented in the following section. In particularly difﬁcult situations,
it is essential that the diagnostic strategies be shared with the referring
clinical geneticist.
As mentioned in the ampliﬁcation-based PGD guidelines,26,27 it is
recommended to perform both indirect (marker based) and direct
(variant based) genetic diagnosis.
PGD diagnostic strategies based on polymorphic markers
Several microsatellite markers within or close to the CFTR gene can be
used in PGD for CF (Table 5). Laboratories may have to search
databases for previously unpublished microsatellite markers in order
to obtain sufﬁcient informative markers for a given couple.
It is recommended to offer PGD using at least two fully informative
ﬂanking markers within a 1-megabase (Mb, equivalent to one million
base pairs) region on both sides of the gene and to include intragenic
markers when available.
As recombination events within the CFTR gene have been very
rarely described, it is acceptable to perform indirect genetic diagnosis
using intragenic microsatellites located on the same side of the variant
if markers ﬂanking the CFTR gene are not informative or gave
inconclusive results.
When MDA is performed, it is recommended to study at least four
fully informative microsatellite markers (two each side of the gene)
because of the higher Allele Drop Out (ADO) rates frequently
reported. Furthermore, semi-informative or noninformative markers
can still be used in an informative haplotype to detect the presence of
contamination and/or chromosomal abnormality (presence of one or
three haplotypes).
All customized protocols must be thoroughly validated before
clinical use.25,26
Table 5 List of markers commonly used in PGD for Cystic Fibrosis
Marker Type UniSTSa Location on chromosome 7b Position according to the CFTR genec Heterozygosity rate (%)
IVS1CA (ca)n NA 117,490,314_117,490,356 Intron 1 75
D7S677 (ca)n 18390 117,499,431_117,499,463 Intron 1 85
IVS8CA (ca)n NA 117,548,335_117,548,367 Intron 9 75
IVS10CA (ca)n NA 117,566,250_117,566,288 Intron 11 89
IVS17BCA (ca)n NA 117,612,236_117,612,262 Intron 20 40
IVS17BTA (ta)n NA 117,612,009_117,612,069 Intron 20 80
D7S2502 (ca)n 30517 115,818,136_115,818,163 Centromeric, 1.65Mb 78
D7S486 (ca)n 1556 116,254,761_116,254,799 Centromeric, 1.21Mb 80
D7S2460 (ca)n 24290 116,767,976_116,768,008 Centromeric, 0.7Mb 71
D7S23 (ca)n 31363 117,322,538_117,322,572 Centromeric, 0.18Mb 85
D7S633 (ca)n 70412 117,370,804_117,370,850 Centromeric, 0.1Mb 45
D7S2847 (tatc)n 64614 119,179,488_119,179,552 Telomeric, 1.46Mb 84
AFM320vb5 (ca)n 31676 118,351,454_118,351,480 Telomeric, 0.64Mb 51
Abbreviation: NA, not applicable.
aUniSTS has migrated to UCSC.
bAccording to UCSC GRCh38/hg38, December 2013.
cExon numbering according to the HGVS nomenclature. Physical distances are taken from location along chromosome 7 according to the UCSC genome browser.
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PGD strategies based on variants identiﬁed in couples
Case 1: p.Phe508del in one or both couple members. As the most
frequent CF variant is the p.Phe508del in exon 11 of the CFTR gene
(exon 10 in the traditional nomenclature), it is very common to
identify this variant in at least one of the couple members (Box 4).
Therefore, it is highly recommended to set up single-cell PCR
conditions for the p.Phe508del variant in combination with indirect
genetic diagnosis to monitor contamination and preclude misdiagnosis
owing to ADO.
For couples in whom one of the partners is heterozygous for a
variant other than p.Phe508del, it is acceptable to perform a direct
diagnosis for the p.Phe508del and an indirect diagnosis for the other
variant, provided sufﬁcient informative markers are available to trace
inheritance of both chromosomes from the non-p.Phe508del carrier.
When there is a lack of informative markers in the parent carrier of
the other variant, it is recommended to speciﬁcally study this causative
variant (in addition to the p.Phe508del) and also to biopsy and
independently analyze two cells instead of one, preferably at the
blastocyst stage.
Case 2: Identical variant (other than p.Phe508del) in both couple
members. It is recommended to develop PCR conditions for the
unique CF-causing variant in addition to indirect genetic diagnosis. It
is acceptable to perform only indirect genetic diagnosis for fully
informative couples (at least two informative markerso1Mb ﬂanking
the gene or one intragenic marker and one ﬂanking marker).
Case 3: Different variants (other than p.Phe508del) in both couple
members. It is acceptable to perform only indirect genetic diagnosis
for fully informative couples (at least two informative markerso1Mb
ﬂanking the gene or one intragenic marker and one ﬂanking marker).
In cases that lack informativity for markers within or near the gene, it
is recommended to speciﬁcally study both causative variants and to
search and add informative markers located further up- or down-
stream. The biopsy and analysis of trophectoderm cells at the
blastocyst stage, should also help in reducing the misdiagnosis risk
due to ADO.
REPORTING
There is currently no formal consensus regarding PGD reports. It also
depends on legislation and ethical laws of each country. However,
according to recommendations for reporting results of diagnostic
genetic testing,44 guidelines for accreditation of the PGD laboratory,45
and recommendations from OECD (Organization for Economic
Co-operation and Development), some important items should be
included in a PGD report. They are listed below.
Feasibility report
 Laboratory issuing results (afﬁliation, address, secretarial phone and
fax numbers)
 Date of report
 Name of the clinician referring the couple
 Unequivocal identiﬁcation of the couple (2 identiﬁers per indivi-
dual, e.g. name and date of birth)
 Specimen information – type of sample and date of sampling (also
time if appropriate)
 Disease (OMIM number, inheritance mode) and gene (OMIM
number) being tested for
 Methods performed and markers used
 Clearly presented results with appropriate interpretative comments
 Appropriate reference intervals
 Error rates clearly stated
 Variant nomenclature using Human Genome Variation Society
(HGVS) recommendations
 Accession number of reference sequence (including version
number)
 Identiﬁcation of individual providing results and authorizer
PGD case report
 Laboratory issuing results (afﬁliation, address, secretarial phone and
fax numbers)
 Referring clinician: name and afﬁliation
 Date of report
 Title, that is ‘PGD for cystic ﬁbrosis’
 Disease (OMIM number and inheritance mode) and gene (OMIM
number) being tested for
 Unequivocal identiﬁcation of both couple members (2 identiﬁers
per individual, e.g. name and date of birth)
 Specimen information: type of sample, date/time of sampling, date
of arrival of samples in the lab
 Methods performed
J List of DNA sequences studied
J Names of the variants analyzed (using HGVS nomenclature)
J Accession number of reference sequence (including version
number)
J Limits of the test (risk of recombination, ADO rate if
indicated)
 Results obtained (genotype may be given or not depending on local
rules). Clearly presented results with appropriate interpretative
comments with clear indication of whether embryos should or
should not be transferred
 Error rates clearly stated
 Identiﬁcation of individual providing results and authorizer
 The report must be signed (some labs sign all steps: experiments,
reading, validation)
 Pagination to include the actual and total number of pages
The reports must be sent (faxed or emailed, depending on legislation
on conﬁdentiality of medical information) to the referring physician
and/or IVF team as described in the ofﬁcial test request form, in time
for embryo transfer. Results should be reported only to persons
authorized to receive and use this kind of medical information. In
some jurisdictions, the lab report must also be sent to the patient
(ie Italy).
Box 4 Genotype coverage in CF
With a frequency of p.Phe508del reaching ~70% of CF alleles in populations
from Northern European descent, almost half of individuals with CF have two
copies of the p.Phe508del allele (p2=(0.7)2=0.49), 42% have one p.Phe508del
in trans with another CFTR variant (2pq=2×0.7×0.3=0.42) and 9% have two
non-p.Phe508del variants (q2=(0.3)2=0.09). Commercially available testing
panels including the 30 most common CF variants detect about 87% of CF
alleles, so that it can be predicted that 24% of patients with CF carry at least one
rare variant not included in these panels (2×0.87×0.13+(0.13)2=0.24). How-
ever, these features can be very different in Southern-European and non-
European populations, who exhibit a much larger proportion of rare variants
and a decreased frequency of p.Phe508del.
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EXTERNAL QUALITY ASSESSMENT
To meet the ISO 15189 standards, accredited laboratories are required
to participate in EQA schemes, which provide an independent
evaluation of the quality of their service and inter-laboratory
comparison, with an educational purpose. The United Kingdom
National External Quality Assessment Service has developed a scheme
speciﬁcally for molecular PGD, based on experience gained with a
three-years pilot scheme for CF-PGD.46 The scheme examines (i) the
ability of each participating lab to genotype genomic DNA and single
cells (ii) the interpretation of results (including the determination of
the limitations of the protocol that was applied for the testing of single
cell samples supplied in the EQA), and (iii) the reporting of PGD
results. The scheme recommendations were followed by the partici-
pating laboratories and led to the improvement in the content of the
reports.
CONCLUDING REMARKS
This meeting organized on behalf of EuroGentest has highlighted
important variation among the participating countries both in
technical protocols and in the counseling of couples. It emphasized
the need to pursue harmonization and quality assurance, preferably
through some form of internationally or nationally recognized
accreditation. Given the complexity of phenotype and genotype
relationships, the extremely high number of variants found in the
CFTR gene, and the reclassiﬁcation of some variants as (non)-
pathogenic as more data become available, genetic counseling is
mandatory, and less common variants should be reviewed with CFTR
experts before acceptance of a PGD CF request.
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